Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026
Pfizer will present data from 57 abstracts, including 12 oral presentations, across its infectious disease pipeline at IDWeek 2026 in Washington, D.C., October 21-24. Key pipeline updates include Phase 2 data for the 25-valent pediatric pneumococcal vaccine candidate (25vPnC) versus PREVNAR 20, Phase 3 VALOR study results for the LB6V Lyme vaccine candidate with BioNTech-partnered COMIRNATY and Valneva-partnered programs also featured, and an EMA review already underway for the Lyme MAA.
Key figures
- Abstract count
- 57
- Oral presentations
- 12
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.